BridgeBio Pharma (BBIO) PT Raised to $50 at Goldman Sachs on Higher Revenue Estimates and M&A Potential
Tweet Send to a Friend
(Updated - July 18, 2023 7:37 AM EDT)
Goldman Sachs analyst Paul Choi raised the price target on BridgeBio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Paul Choi raised the price target on BridgeBio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
